- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Kentuckians Urged to Update Vaccines Following Drop in Immunization Rates During Pandemic
Kentucky Medical Association, Anthem Blue Cross and Blue Shield, Kentucky Foundation for Medical Care, and Foundation For A Health Kentucky team up to launch “Raise Your Guard, KY” campaign.
Louisville, Kentucky - A new campaign designed to counter the sharp decline in vaccination rates among Kentucky children launched today across the state. Raise Your Guard, KY urges Kentuckians to contact their physicians to get themselves and their families back on track with scheduled immunizations to prevent dozens of life-threatening diseases and illnesses. The month-long, multimedia campaign also reminds residents to get their annual flu shots starting in September to help keep their immune systems strong.
Raise Your Guard, KY is funded by the Foundation for a Healthy Kentucky, the Kentucky Medical Association, the Kentucky Foundation for Medical Care and Anthem Blue Cross Blue Shield in Kentucky. Governor Andy Beshear will announce the campaign today by showing a brief video during his afternoon COVID-19 media briefing.
“Disparities persist between Medicaid beneficiaries and Kentuckians with private insurance in terms of immunization rates,” noted Eric Friedlander, secretary of the Cabinet for Health and Family Services. “Immunization Awareness Month is the ideal time to take actions that lead to closing this gap."
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
